Irbesartan Hydrochlorothiazide BMS (irbesartan;hydrochlorothiazide)
- Region
- 🇪🇺 EU
- Active substance
- irbesartan;hydrochlorothiazide
- Company
- Bristol-Myers Squibb Pharma EEIG
- Status
- Withdrawn
- Therapeutic area
- Hypertension
- EU approval
- Fri 19 Jan 2007
- Application
- EMEA/H/C/000784
- ATC
- C09DA04
- Official record
- www.ema.europa.eu
Indication
Treatment of essential hypertension.This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop) Authorised · sanofi-aventis groupe
- 🇪🇺 Ifirmacombi Authorised · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 Irbesartan/Hydrochlorothiazide Teva Authorised · Teva B.V.
- 🇪🇺 Karvezide Authorised · Sanofi Winthrop Industrie
- 🇪🇺 CoAprovel Authorised · Sanofi Winthrop Industrie
Follow Irbesartan Hydrochlorothiazide BMS
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.